| Not Yet Recruiting | Testing Two Different Drugs (Sacituzumab-govitecan and Trastuzumab-deruxtecan) Combinations Prescribed in an A NCT07151586 | UNICANCER | Phase 2 |
| Not Yet Recruiting | A Study of Sacituzumab Govitecan Plus Toripalimab Versus Toripalimab Plus Nab-Paclitaxel in PD-L1 Positive Adv NCT07040644 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Phase 2 |
| Recruiting | A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) NCT06966700 | Merck Sharp & Dohme LLC | Phase 3 |
| Recruiting | A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK NCT06841354 | Merck Sharp & Dohme LLC | Phase 3 |
| Recruiting | Capecitabine Plus Pembrolizumab in Patients With Triple Negative Breast Cancer After Chemo-immunotherapy and S NCT05973864 | UNICANCER | Phase 2 |
| Recruiting | A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors NCT06586957 | NiKang Therapeutics, Inc. | Phase 1 |
| Recruiting | Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer NCT05485766 | Okayama University | Phase 2 |
| Recruiting | A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer NCT06380816 | Cancer Research UK | Phase 1 / Phase 2 |
| Recruiting | A Study of LY4170156 in Participants With Selected Advanced Solid Tumors NCT06400472 | Eli Lilly and Company | Phase 1 |
| Recruiting | A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors NCT06157892 | Seagen, a wholly owned subsidiary of Pfizer | Phase 2 |
| Recruiting | Bicalutamide and Abemaciclib in Inoperable or Metastatic Androgen Receptor-positive Triple-negative Breast Can NCT06365788 | Universitaire Ziekenhuizen KU Leuven | Phase 2 |
| Terminated | "neoBREASTIM": Atezolizumab Plus RP1 Oncolytic Immunotherapy in the NeoAdjuvant Setting of Triple-Negative Bre NCT06067061 | Institut Curie | Phase 1 / Phase 2 |
| Recruiting | Utidelone (UTD1) Plus Capecitabine in Non-pCR TNBC After Neoadjuvant Therapy NCT06385990 | Hunan Cancer Hospital | Phase 2 |
| Terminated | A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors NCT06264921 | NiKang Therapeutics, Inc. | Phase 1 |
| Recruiting | A Study of Pembrolizumab and Cryoablation in People With Breast Cancer NCT06246968 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Unknown | Comparative Efficacy of Xiaopi Granules and Decoction in Triple-negative Breast Cancer: a Randomized Controlle NCT06154109 | Zhiyu Wang | Phase 2 |
| Withdrawn | Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study NCT06057636 | The University of Tennessee, Knoxville | N/A |
| Recruiting | Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer NCT05020860 | Baylor Breast Care Center | Phase 2 |
| Active Not Recruiting | A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advance NCT05544929 | Novartis Pharmaceuticals | Phase 1 |
| Recruiting | A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors NCT05208762 | Seagen, a wholly owned subsidiary of Pfizer | Phase 1 |
| Terminated | Image-based AI Predictive Biomarkers for Precision Neoadjuvant Triple-negative Breast Cancer Treatment NCT05435352 | Ourotech, Inc. | — |
| Terminated | NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid NCT05252390 | Nuvation Bio Inc. | Phase 1 |
| Terminated | A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors NCT05194072 | Seagen, a wholly owned subsidiary of Pfizer | Phase 1 |
| Not Yet Recruiting | Cyclin dEpendent Kinase in tRiple nEGatIVe brEast canceR - a "Window of Opportunity" Study NCT05067530 | Medical University of Gdansk | Phase 2 |
| Completed | MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) NCT05007106 | Merck Sharp & Dohme LLC | Phase 2 |
| Completed | A Study of TAK-676 With Pembrolizumab After Radiation Therapy to Treat a Number of Cancers NCT04879849 | Takeda | Phase 1 |
| Recruiting | A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advan NCT04895709 | Bristol-Myers Squibb | Phase 1 / Phase 2 |
| Unknown | Psychological Factors and Oncological Outcomes of Triple-negative Breast Cancer NCT04669522 | Pius-Hospital Oldenburg | — |
| Terminated | Bintrafusp Alfa in High Mobility Group AT-Hook 2 (HMGA2) Expressing Triple Negative Breast Cancer NCT04489940 | EMD Serono Research & Development Institute, Inc. | Phase 2 |
| Completed | First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours NCT04504669 | AstraZeneca | Phase 1 |
| Active Not Recruiting | Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies NCT04561362 | BicycleTx Limited | Phase 1 / Phase 2 |
| Terminated | Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry NCT04251533 | Novartis Pharmaceuticals | Phase 3 |
| Active Not Recruiting | NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBC NCT04335669 | Lund University Hospital | Phase 3 |
| Completed | Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction With First-Line Ch NCT04191135 | Merck Sharp & Dohme LLC | Phase 2 |
| Terminated | Neoantigen DNA Vaccine Alone vs. Neoantigen DNA Vaccine Plus Durvalumab in Triple Negative Breast Cancer Patie NCT03199040 | Washington University School of Medicine | Phase 1 |
| Unknown | Evaluate the Clinical Benefit of a Post-operative Treatment Associating Radiotherapy + Nivolumab + Ipilimumab NCT03818685 | Centre Leon Berard | Phase 2 |
| Active Not Recruiting | Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC NCT03997123 | AstraZeneca | Phase 3 |
| Terminated | Leronlimab (PRO 140) Combined With Carboplatin in Patients With Cytokine Chemokine Receptor 5 Positive (CCR5+) NCT03838367 | CytoDyn, Inc. | Phase 1 / Phase 2 |
| Active Not Recruiting | A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer NCT03742102 | AstraZeneca | Phase 1 / Phase 2 |
| Unknown | Safety and Efficacy of SCT200 in Patients With Relapsed or Metastatic Triple Receptor Negative Breast Cancer NCT03692689 | Sinocelltech Ltd. | Phase 2 |
| Completed | Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Ne NCT03310957 | Seagen Inc. | Phase 1 / Phase 2 |
| Completed | Study of Boserolimab (MK-5890) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Adults With A NCT03396445 | Merck Sharp & Dohme LLC | Phase 1 |
| Terminated | Study of Pembrolizumab and Mifepristone in Patients With Advanced HER2-negative Breast Cancer NCT03225547 | University of Chicago | Phase 2 |
| Completed | A Study of the Efficacy and Safety of Atezolizumab Plus Chemotherapy for Patients With Early Relapsing Recurre NCT03371017 | Hoffmann-La Roche | Phase 3 |
| Completed | A Study of AK-01 (LY3295668) in Solid Tumors NCT03092934 | Eli Lilly and Company | Phase 1 / Phase 2 |
| Terminated | Window of Opportunity Trial of Dasatinib in Operable Triple Negative Breast Cancers With nEGFR NCT02720185 | University of Wisconsin, Madison | Phase 2 |
| Completed | Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pem NCT03036488 | Merck Sharp & Dohme LLC | Phase 3 |
| Terminated | Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple NCT02978716 | G1 Therapeutics, Inc. | Phase 2 |
| Completed | Assessing the Efficacy of Paclitaxel and Olaparib in Comparison to Paclitaxel / Carboplatin Followed by Epirub NCT02789332 | GBG Forschungs GmbH | Phase 2 |
| Terminated | A Study of TAK-659 in Combination With Nivolumab in Participants With Advanced Solid Tumors NCT02834247 | Calithera Biosciences, Inc | Phase 1 |
| Completed | Adjuvant Treatment for High-risk Triple Negative Breast Cancer Patients With the Anti-PD-l1 Antibody Avelumab NCT02926196 | Istituto Oncologico Veneto IRCCS | Phase 3 |
| Completed | Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors NCT02658214 | AstraZeneca | Phase 1 |
| Withdrawn | A Study of Neoadjuvant Paclitaxel in Combination With Bavituximab in Early- Stage Triple- Negative Breast Canc NCT02685306 | Peregrine Pharmaceuticals | Phase 2 |
| Completed | Safety and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy as Neoadjuvant Treatment NCT02622074 | Merck Sharp & Dohme LLC | Phase 1 |
| Withdrawn | The Clinical Significance of Cellular Immune Adjuvant Therapy of Triple Negative Breast Cancer NCT02539017 | First Affiliated Hospital Xi'an Jiaotong University | Phase 2 |
| Withdrawn | Safety and Immunogenicity of a Personalized Synthetic Long Peptide Breast Cancer Vaccine Strategy in Patients NCT02427581 | Washington University School of Medicine | Phase 1 |
| Completed | Safety and Immunogenicity of a Personalized Polyepitope DNA Vaccine Strategy in Breast Cancer Patients With Pe NCT02348320 | Washington University School of Medicine | Phase 1 |
| Terminated | A Study Evaluating PF-03084014 In Patients With Advanced Breast Cancer With Or Without Notch Alterations NCT02299635 | Pfizer | Phase 2 |
| Terminated | Neoadjuvant Treatment of Triple Negative Breast Cancer Patients With Docetaxel and Carboplatin to Assess Anti- NCT02124902 | Washington University School of Medicine | Phase 2 |
| Completed | A Safety Study of SGN-LIV1A in Breast Cancer Patients NCT01969643 | Seagen Inc. | Phase 1 |
| Completed | Triple-negative Breast Cancer: a New Perspective on Biomarkers NCT03539965 | Instituto Nacional de Cancer, Brazil | — |